ÃÖ½Å³í¹®¸®ºä
   
Magnesium Supplementation and the Effects on Wound Healing and Metabolic Status in Patients with Diabetic Foot Ulcer: a Randomized, Double-Blind, Placebo-Controlled Trial
±Û¾´ÀÌ : °ü¸®ÀÚ ³¯Â¥ : 2018-09-21 (±Ý) 12:10 Á¶È¸ : 1759
Razzaghi2018_Article_MagnesiumSupplementationAndThe.pdf (467.4K), Down : 1, 2018-09-21 12:10:43

Magnesium Supplementation and the Effects on Wound Healing and Metabolic Status in Patients with Diabetic Foot Ulcer: a Randomized, Double-Blind, Placebo-Controlled Trial

 

Razzaghi, Reza, et al. "Magnesium supplementation and the effects on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial." Biological trace element research 181.2 (2018): 207-215.

 

 

Introduction

´ç´¢ ȯÀÚÀÇ ¾à 25%¿¡¼­ ´ç´¢º´¼º ½Å°æº´ÁõÀÌ ¹ß»ýÇϸç, ¸»ÃʽŰ溴Áõ°ú ¸»ÃÊÇ÷°üÁúȯ¿¡ ÀÇÇÏ¿© ´ç´¢¹ß ±Ë¾ç(diabetic foot ulcer, DFU)ÀÇ ¹ß»ý À§Ç輺À» Áö´Ñ´Ù. ´Ù¸¥ ¿¬±¸¿¡ µû¸£¸é hyperglycemia, insulin resistance, dyslipidemia´Â ¿°ÁõÀ» Áõ°¡½ÃÅ°°í reactive oxygen (ROS)/nitrogen ±×·ì¿¡ ÀÇÇؼ­ DFU º´¸®ÀÇ ÁÖ¿äÇÑ ¿ªÇÒÀº ÇÑ´Ù°í ÇÑ´Ù.

 

Hypomagnesemia´Â ´ç´¢º´¼º ½Å°æº´Áõ ¹ß»ý ¹× Ç÷¼ÒÆDZâ´É°ú °ü·ÃÀÌ ÀÖÀ½ÀÌ º¸°í µÇ¾úÀ¸¸ç, ÀÌ·Î ÀÎÇÏ¿© hypomagnesemia´Â DFUÀÇ À§Çè ÀÎÀÚÀÌ´Ù. Magnesium supplementationÇÏ°Ô µÇ¸é metabolic profiles (HDL Á¦¿Ü)¿Í biomarkers of inflammation and oxidative stress °¨¼Ò ½ÃÅ°¸ç ÀÌ¿Í °°ÀºÀÛ¿ëÀº acetyl-CoA carboxylase enzyme È¿°ú, »ý¸®Àû Àν¶¸° ºÐºñ ÁõÁø ±×¸®°í nuclear factor-kappa B (NF-kappa B) ¾ïÁ¦¸¦ ÅëÇÏ¿© ÀÌ·ïÁø´Ù.

 

º» ¿¬±¸ÀúÀÚµéÀº DFU ȯÀÚ¿¡¼­ magnesium supplementationÀÌ metabolic profiles È£Àü°ú biomarkers of inflammation °¨¼Ò ±×¸®°í and oxidative stress ¿ÏÈ­¸¦ ÅëÇÏ¿© DFUÀÇ Ä¡·á°æ°ú ºü¸£°Ô µÉ °ÍÀ̶ó°í °¡Á¤ÇÏ°í À̸¦ È®ÀÎ ÇÏ°íÀÚ ÇÏ¿´´Ù.

 

 

Methods

randomized double-blind placebo-controlled clinicaltrial·Î¼­ 40~85¼¼, Wagner-Meggitt¡¯s criteria grade 3 DFU 70¸íÀ» ´ë»óÀ¸·Î ÁøÇàÇÏ¿´´Ù. (grade 3´Â deep ulcer with abscess or osteomyelitis)

12ÁÖ µ¿¾È 35¸í¾¿ 2±ºÀ¸·Î ÇÏ¿© ½ÇÇ豺Àº 250mg/day magnesium oxide [21st

Century Pharmaceutical Company (AZ, USA)]¸¦ Á¦°øÇÏ¿´°í ´ëÁ¶±ºÀº placebo [Barij

Essence Pharmaceutical Company (Kashan, Iran)]¸¦ Åõ¿©ÇÏ¿´´Ù. ½ÇÇè¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ´Â ±âŸ ¿ä¼Ò (½Ä»ç Á¾·ù ¹× ½Ä»ç·®, ¿îµ¿·® È°µ¿·® µî)Àº µ¿ÀÏÇÏ°Ô À¯ÁöÇÏ¿´´Ù. (Ç¥ 1)

 

 

Primary outcome Àº wound healing°ú glucose metabolismÀÇ º¯È­¸¦ È®ÀÎ ÇÏ°íÀÚ ÇÏ¿´°í lipid profiles, markers of inflammation and oxidative stress´Â secondary outcomeÀ¸·Î È®ÀÎÇÏ¿´°í, Ulcer Æò°¡´Â ulcerÀÇ ±æÀÌ (°¡Àå ±ä Ãà)¿Í ±íÀÌ (sterile blunt nasal probeÀ» ÀÌ¿ëÇÏ¿© ÃøÁ¤)¸¦ È®ÀÎÇÏ¿© Æò°¡ ÇÏ¿´À¸¸ç ³ª¸ÓÁö Æò°¡¿ä¼Ò´Â Ç¥ 2,3¿¡¼­ È®ÀÎ ÇÒ ¼ö ÀÖ´Ù.

 

Discussion

12ÁÖ µ¿¾È magnesium supplementationÀ» ½ÃÇàÇÑ ±º¿¡¼­ ulcer size, glucose metabolism, serum hs-CRP, and plasma TAC levels¿¡¼­ È£ÀüÀ» È®ÀεǾú°í lipid profiles, other biomarkers of inflammation and oxidative stress¿¡´Â Å« ¿µÇâÀ» ÁÖÁö ¾Ê¾Ò´Ù. ¸ðµç ȯÀÚ¿¡¼­ off-loading, insole, ÀûÀýÇÑ ½Å¹ß µîÀÇ ±âº»ÀûÀÎ ³»¿ëÀº µ¿ÀÏÇÏ°Ô Àû¿ëÇÏ¿´À½¿¡µµ magnesium º¹¿ë±º¿¡¼­ º¸´Ù ÀÇ¹Ì Àִ ȣÀüÀÌ °üÂûµÈ °ÍÀº ÁÖ¸ñÇÒ ¸¸ÇÏ°Ú´Ù. (56.7% for magnesium vs. 28.1% for placebo group, P = 0.02).

º» ¿¬±¸¿¡¼­ 250mg/day¸¦ Á¦°øÇÏ¿´°í HOMA-IR, HOMA-B, lipid profile¿¡ º¯È­¸¦ È®ÀÎÇÒ ¼ö ¾ø¾úÁö¸¸ 365mg/dayÀ» Á¦°øÇÑ ´Ù¸¥ ¿¬±¸¿¡¼­´Â parameters of insulin metabolismÀÇ È£ÀüÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù°í ÇÑ´Ù.

 

Conclusion

12ÁÖ µ¿¾È magnesium supplementation (250mg/day)À» DFU ȯÀÚ¿¡°Ô Á¦°ø ½Ã lipid profilesÀ̳ª other biomarkers of inflammation and oxidative stress¸¦ Á¦¿ÜÇÑ parameters of ulcer size, glucose metabolism, serum hs-CRP, and plasma TAC levelsÀÇ ±àÁ¤Àû È¿°ú¸¦ ±â´ëÇÒ ¼ö ÀÖ°Ú´Ù.


À̸§ Æнº¿öµå
ºñ¹Ð±Û (üũÇÏ¸é ±Û¾´À̸¸ ³»¿ëÀ» È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.)
¿ÞÂÊÀÇ ±ÛÀÚ¸¦ ÀÔ·ÂÇϼ¼¿ä.